| Autor: |
Reneman, Liesbeth, Booij, Jan, Habraken, Jan B.A., De Bruin, Kora, Hatzidimitriou, George, Den Heeten, Gerard J., Ricaurte, George A. |
| Zdroj: |
Synapse; December 2002, Vol. 46 Issue: 3 p199-205, 7p |
| Abstrakt: |
Recent [123I]β‐CIT single‐photon emission computed tomography (SPECT) studies revealed decreased serotonin transporters (SERT) density in the brain of humans with a history of MDMA (“Ecstasy”) use. However, [123I]β‐CIT SPECT has until now not been validated as a method for detecting such serotonergic lesions. Therefore, the present study was undertaken. Following baseline [123I]β‐CIT SPECT scans, a rhesus monkey was treated with MDMA (5 mg/kg, s.c. twice daily for 4 consecutive days). SPECT studies 4, 10, and 31 days after MDMA treatment revealed decreases in [123I]β‐CIT binding ratios in the SERT‐rich brain region studied (hypothalamic/midbrain region), with SERT density reduced by 39% in this brain region 31 days after treatment. Data obtained with SPECT studies correlated well with SERT density determined with autoradiography after sacrifice of the animal (−34%). In addition, ex vivo [123I]β‐CIT binding studies in rats 1 week after treatment with neurotoxic doses of MDMA (20 mg/kg s.c. twice daily for 4 consecutive days) revealed significant reductions in [123I]β‐CIT binding in SERT‐rich regions (including the hypothalamus) when compared to saline‐treated rats. The combined results of these studies indicate that SPECT imaging of SERT with [123I]β‐CIT can detect changes in SERT density secondary to MDMA‐induced neurotoxicity in the hypothalamic/midbrain region, and possibly other brain regions. Synapse 46:199–205, 2002. © 2002 Wiley‐Liss, Inc. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Plný text